

## ERTUGLIFLOZIN film-coated tablets (Steglatro® ▼) as part of a triple therapy regimen for type 2 diabetes

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ERTUGLIFLOZIN film-coated tablets (Steglatro® ▼) for use as part of a triple therapy regimen for the treatment of type 2 diabetes.**

### GREY

Ertugliflozin is licensed in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

- > as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.
- > in addition to other medicinal products for the treatment of diabetes.<sup>[1]</sup>

This recommendation will be reviewed when the NICE TA is published. This is expected to be in June 2019.

See separate Pan Mersey APC policy statement for the use of [ertugliflozin as monotherapy or as dual therapy](#) with metformin.

In the meantime, prescribers should continue to follow local and national guidance on the treatment of type 2 diabetes, and the use of SGLT-2 inhibitors:

- > National Institute for Health and Care Excellence: [Type 2 diabetes in adults pathway](#) (last updated November 2018).
- > National Institute for Health and Care Excellence: [NG28 Type 2 diabetes in adults: management](#) (last updated May 2017)
- > Pan Mersey Area Prescribing Committee: [Canagliflozin, Dapagliflozin and Empagliflozin as combination therapies: a multiple prescribing statement](#) (last updated November 2017)
- > Pan Mersey Area Prescribing Committee: [Canagliflozin, Dapagliflozin and Empagliflozin as monotherapies: a multiple prescribing statement](#) (last updated November 2017)

### References

1. Merck, Sharp and Dohme Limited. Summary of Product Characteristics: [Steglatro 5 mg and 15 mg film-coated tablets](#), 28 August 2018. Accessed online 26 February 2019.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.